Bausch + Lomb reported that its 24‑month pivotal U.S. trial of the ELIOS System met all primary effectiveness endpoints for patients with open‑angle glaucoma. The implant‑free procedure, which uses next‑generation excimer laser technology, achieved a 76 % rate of at least a 20 % reduction in unmedicated diurnal intraocular pressure (IOP) and an average IOP drop of 7.4 mmHg. At 23 months, 82 % of participants were medication‑free, and the safety profile was comparable to cataract surgery alone, with no intraoperative complications reported.
The study enrolled 318 patients across 20 U.S. sites, all of whom were on glaucoma medications at baseline. The sustained IOP reduction and high medication‑free rate demonstrate the ELIOS System’s potential to become a new standard of care for patients who are intolerant of or seek alternatives to medication or traditional surgery. The implant‑free, tissue‑friendly approach aligns with the growing demand for minimally invasive glaucoma surgery (MIGS) and offers a streamlined option that can be combined with cataract surgery.
The ELIOS System is CE‑marked in Europe and has been available there for several years, providing a robust safety and efficacy record. In the United States, the technology has not yet been reviewed by the FDA for safety or effectiveness; Bausch + Lomb is targeting a U.S. launch in the second half of 2026. The company’s acquisition of Elios Vision Inc. in December 2024 further underscores its commitment to expanding its glaucoma treatment portfolio.
Bausch + Lomb’s broader financial context shows a 2025 revenue of $5.101 billion and a GAAP net loss of $360 million, with 2026 revenue guidance of $5.375 billion to $5.475 billion. While the company has faced headwinds in its legacy segments, the positive clinical data for ELIOS provides a potential high‑margin, implant‑free surgical option that could strengthen its market position in the projected $6.69 billion glaucoma treatment market.
Yehia Hashad, Executive Vice President, R&D and Chief Medical Officer, said, "Achieving meaningful reductions in intraocular pressure and freedom from medication for a majority of patients speaks to the promise of this technology." Luc Bonnefoy, President of the Surgical Division, added, "The ELIOS system offers a differentiated approach for the treatment of glaucoma, a condition expected to increase in prevalence by 47 % from 2020 to 2040." "ELIOS provides a tissue‑friendly, precision non‑thermal laser‑based and highly adoptable procedure for the treatment of glaucoma. The synergy between cataract surgery and MIGS can help ophthalmologists provide streamlined care and improve patient quality of life," said Ike K. Ahmed, MD, Ophthalmologist. "The ELIOS procedure shows exciting potential for minimally invasive glaucoma treatment in the U.S., leveraging precision excimer laser technology to enhance the eye's natural outflow pathways. I believe glaucoma and cataract specialists alike will be very interested in the consistency of these impressive results as well as the demonstrated strong safety profile," commented Mark J Gallardo, MD, Glaucoma Fellowship Director at El Paso Eye Surgeons.
revised_sentiment_rating":5} }
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.